UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2006 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Juris- (Commission File (IRS Employer diction of Incorporation) Number) Identification No.) One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: 732-524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On October 6, 2006, the Company issued a press release announcing that Robert J. Darretta, the Company's Vice Chairman of the Board of Directors and Chief Financial Officer, has elected to retire in early 2007. The Company also announced that Dominic J. Caruso, Vice President of the Company's Group Finance organization, has been appointed Corporate Vice President, Finance and Chief Financial Officer, effective January 1, 2007. Mr. Caruso will report to William C. Weldon, the Company's Chairman and Chief Executive Officer, and become a member of the Company's Executive Committee. Mr. Caruso, 49, has led the Company's Group Finance organization since December 2005. Previously, he was Vice President, Group Finance for the Medical Devices and Diagnostics (MD&D) Group and a member of the MD&D Group Operating Committee. In 2001, Mr. Caruso became Vice President, Finance for Ortho-McNeil Pharmaceutical, Inc. and a member of its Management Board, before being named to the MD&D position in May 2003. Mr. Caruso joined Johnson & Johnson in October 1999 through the acquisition of Centocor, Inc. where he was Vice President, Finance. A copy of the press release is attached as Exhibit 99 to this report. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JOHNSON & JOHNSON (Registrant) Date: October 12, 2006 By: /s/ Steven M. Rosenberg Steven M. Rosenberg Secretary EXHIBIT INDEX Exhibit No. Description 99 Press release dated October 6, 2006.